Regulatory B cells need alpha 4 integrin to get into the brain

R
Lehmann-Horn K, Sagan SA, Winger RC, Spencer CM, Bernard CC, Sobel RA, Zamvil SS.CNS accumulation of regulatory B cells is VLA-4-dependent.Neurol Neuroimmunol Neuroinflamm. 2016 ;3(2):e212.


OBJECTIVE:To investigate the role of very late antigen-4 (VLA-4) on regulatory B cells (Breg) in CNS autoimmune disease.
METHODS: Experimental autoimmune encephalomyelitis (EAE) was induced in mice selectively deficient for VLA-4 on B cells (CD19cre/α4(f/f)) by immunization with myelin oligodendrocyte glycoprotein (MOG) peptide (p)35-55 or recombinant human (rh) MOG protein. B-cell and T-cell populations were examined by flow cytometry and immunohistochemistry. Breg were evaluated by intracellular IL-10 staining of B cells and, secondly, by coexpression of CD1d and CD5.
RESULTS: As previously reported, EAE was less severe in B-cell VLA-4-deficient vs control CD19cre mice when induced by rhMOG, a model that is B-cell-dependent and leads to efficient B-cell activation and antibody production. Paradoxically, B-cell VLA-4-deficient mice developed more severe clinical disease than control mice when EAE was induced with MOG p35-55, a B-cell-independent encephalitogen that does not efficiently activate B cells. Peripheral T-cell and humoral immune responses were not altered in B-cell VLA-4-deficient mice. In MOG p35-55-induced EAE, B-cell VLA-4 deficiency reduced CNS accumulation of B but not T cells. Breg were detected in the CNS of control mice with MOG p35-55-induced EAE. However, more severe EAE in B-cell VLA-4-deficient mice was associated with virtual absence of CNS Breg.
CONCLUSIONS: Our results demonstrate that CNS accumulation of Breg is VLA-4-dependent and suggest that Breg may contribute to regulation of CNS autoimmunity in situ. These observations underscore the need to choose the appropriate encephalitogen when studying how B cells contribute to pathogenesis or regulation of CNS autoimmunity.



Is EAE being turned in to a B cell disease as ocrelizumab gets nearer the clinic. 
This study says that rather than have consistent disease severity in your experiments if you want to get your treatment to have a lesser effect, make sure you have a control score of mean 4, but if you want to show that your treatment makes things worse make sure your control group is mean 2:-)
Only kidding. It says that you have to induce your disease in a certain way do it with whole protein you get one thing do it with a peptide of the same protein you get a different thing. It has been argued that it is all to so with processing of antigen, but in this study it says if you block the target for natalizumab then B regulatory cells don’t get into the CNS and have more severe disease, so does this tell us that the role of natalizumab is to block T cells because if the major action was on the B cell then would MS not get worse?. So more support for the role of T cells in MS. However, if you look at the disease profile it suggests that the influence is not on disease development but on disease inhibition once started.

About the author

MouseDoctor

1 comment

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives